In April 2012, Belgian Volition, VolitionRX's research and development subsidiary for Nucleosomics, moved into a new office and lab space. The new, much larger, space comprises an office, meeting room and a laboratory, and is a standalone facility, which is required for ISO certification and European and FDA approvals.
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.
VolitionRX products are based on a unique and proprietary technology platform, Nucleosomics™, which enables the measurement and identification of nucleosomes in the blood, using simple, inexpensive blood tests.
VolitionRX is managed by a team with extensive experience in diagnostics and commercialization. VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
VolitionRX is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.
Forward-Looking Statements: Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or ma
|SOURCE VolitionRX Limited|
Copyright©2010 PR Newswire.
All rights reserved